The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com



Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Mar. 28, 8:32 AM

Slide #23. Cognition Therapeutics, Inc. Secondary Offering

Company: Cognition Therapeutics, Inc. (NASDAQ:CGTX)
Date announced: 3/11/2024
Shares Offered: 6,571,428
Date of Pricing: 3/11/2024
Price Per Share: $1.75
Secondary Offering Details: Cognition Therapeutics, Inc. ("Cognition," the "Company" or "We") (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock. Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the proposed offering will be sold by Cognition. -updated 3/11- Cognition Therapeutics, Inc. ("Cognition," the "Company" or "We") (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions.

Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid.
Open the CGTX Page at The Online Investor »

Company Name:  Cognition Therapeutics Inc
Website:  www.cogrx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding CGTX:  3
Total Market Value Held by ETFs:  $1.71M
Total Market Capitalization:  $55.00M
% of Market Cap. Held by ETFs:  3.11%
 

Open the CGTX Page at The Online Investor (in a new window) »

March 28, 2024    8:32 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree CGTX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.